Home Alzheimer’s Disease Thierry André, MD, on Interim Results from the Phase III Keynote-177 Study

Thierry André, MD, on Interim Results from the Phase III Keynote-177 Study

Results from an interim analysis of the randomized, open-label phase III KEYNOTE-177 study indicated that front-line therapy with the immune checkpoint inhibitor pembrolizumab (Keytruda) doubled progression-free survival (PFS) compared to chemotherapy in patients with advanced colorectal cancer.

The findings, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, are the first to show benefit with pembrolizumab in this patient population when used as a front-line therapy. 

Thierry André, MD, of the Sorbonne Université and Hôpital Saint Antoine in Paris, spoke with CancerNetwork® about the implications of the study and how these long awaited trial results could alter the current standard of care.

Transcription:

For me, it’s a good way to deal with the patients. Because it’s not to give a product for a large population and to obtain the…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments